Brief: Elekta Signs Joint Venture With Sinopharm, To Increase Radiotherapy Adoption In China
March 14 (Reuters) - Elekta AB EKTAb.ST :
* ELEKTA AND SINOPHARM COLLABORATE TO IMPROVE ACCESS AND
QUALITY
OF CANCER CARE IN CHINA
* SIGNED A JOINT VENTURE WITH CHINA NATIONAL PHARMACEUTICAL
GROUP
CO., LTD. (SINOPHARM)
* TO INCREASE ADOPTION OF RADIATION THERAPY IN SO-CALLED
LOWER-TIER CITIES, WHERE AROUND 70 PERCENT OF POPULATION RESIDES
Source text for Eikon: ID:nMFNt8tfb
Further company coverage: EKTAb.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Sinopharm
See all newsBrief: Sinopharm Group Says 9M Sinopharm Accord Net Income Attributable RMB952.5 Million (Oct 20)
Medical products distributor Sinopharm Group's prelim 9-month revenue slips
Brief: BlackRock's Long Position In H Shares Of Sinopharm Reduces To 9.23% On Oct 13, HKEX Shows
Sinopharm interim revenue edges down on softness in pharmaceutical distribution business
Brief: Sinopharm Group To Sell 30.13% Stake In China National Medicines Guorui Pharmaceutical For